{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T07:16:44Z","timestamp":1784791004002,"version":"3.55.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"vor","delay-in-days":365,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.ijid.2012.07.009","type":"journal-article","created":{"date-parts":[[2012,8,28]],"date-time":"2012-08-28T05:45:29Z","timestamp":1346132729000},"page":"e843-e849","source":"Crossref","is-referenced-by-count":30,"title":["A prospective, randomized, double dummy, placebo-controlled trial of oral cefditoren pivoxil 400mg once daily as switch therapy after intravenous ceftriaxone in the treatment of acute pyelonephritis"],"prefix":"10.1016","volume":"16","author":[{"given":"Teerapong","family":"Monmaturapoj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preecha","family":"Montakantikul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piroon","family":"Mootsikapun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pramote","family":"Tragulpiankit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2012.07.009_bib0005","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1086\/519267","article-title":"Antibiotic resistance and pyelonephritis","volume":"45","author":"Foxman","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2012.07.009_bib0010","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1086\/520427","article-title":"Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA)","volume":"29","author":"Warren","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2012.07.009_bib0015","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.clinthera.2008.10.007","article-title":"Short-versus long-course antibiotic therapy for acute pyelonephritis in adolescents and adults: a meta-analysis of randomized controlled trials","volume":"30","author":"Kyriakidou","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijid.2012.07.009_bib0020","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1001\/jama.283.12.1583","article-title":"Comparison of ciprofloxacin (7 days) and trimethoprim\u2013sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women: a randomized trial","volume":"283","author":"Talan","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.ijid.2012.07.009_bib0025","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2012.07.009_bib0030","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.amjmed.2008.04.039","article-title":"Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates","volume":"121","author":"Johnson","year":"2008","journal-title":"Am J Med"},{"key":"10.1016\/j.ijid.2012.07.009_bib0035","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jinf.2008.07.004","article-title":"Resistance to fluoroquinolones and treatment failure\/short-term relapse of community-acquired urinary tract infections caused by Escherichia coli","volume":"57","author":"Gaglitti","year":"2008","journal-title":"J Infect"},{"key":"10.1016\/j.ijid.2012.07.009_bib8","unstructured":"National Institute of Health (Internet). Nonthaburi; 2010 (cited 2012 Feb 20). National Antimicrobial Resistance Surveillance Center of Thailand. Available from: http:\/\/narst.dmsc.moph.go.th\/a8.php."},{"key":"10.1016\/j.ijid.2012.07.009_bib0045","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1128\/AAC.00123-06","article-title":"Fluoroquinolone-resistant urinary isolates of Escherichia coli from outpatients are frequently multidrug resistant: results from the North American Urinary Tract Infection Collaborative Alliance-Quinolone Resistance Study","volume":"50","author":"Karlowsky","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2012.07.009_bib0050","first-page":"933","article-title":"Diagnosis and management of acute pyelonephritis in adults","volume":"71","author":"Ramakrishnan","year":"2005","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.ijid.2012.07.009_bib0055","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/emj.19.1.19","article-title":"Short term effectiveness of ceftriaxone single dose in the initial treatment of acute uncomplicated pyelonephritis in women. A randomized controlled trial","volume":"19","author":"Sanchez","year":"2002","journal-title":"Emerg Med J"},{"key":"10.1016\/j.ijid.2012.07.009_bib0060","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/jac\/dkh208","article-title":"Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy","volume":"53","author":"Wells","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2012.07.009_bib0065","first-page":"51","article-title":"Pharmacokinetic\/pharmacodynamic serum and urine profile of cefditoren following single-dose and multiple twice- and thrice-daily regimens in healthy volunteers: a phase I study","volume":"20","author":"Sadaba","year":"2007","journal-title":"Rev Esp Quimioterap"},{"key":"10.1016\/j.ijid.2012.07.009_bib0070","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.diagmicrobio.2010.02.013","article-title":"Comparative in vitro activity of cefditoren and other antimicrobials against Enterobacteriaceae causing community-acquired uncomplicated urinary tract infections in women: a Spanish nationwide multicenter study","volume":"67","author":"Cuevas","year":"2010","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijid.2012.07.009_bib0075","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ijantimicag.2007.05.011","article-title":"In vitro activity of cefditoren against clinical isolates of Escherichia coli from a Korean hospital","volume":"30","author":"Ko","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijid.2012.07.009_bib0080","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0732-8893(00)00135-8","article-title":"Cefditoren activity against nearly 1000 non-fastidious bacterial isolates and the development of in vitro susceptibility test methods","volume":"37","author":"Jones","year":"2000","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijid.2012.07.009_bib0085","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1128\/AAC.01247-07","volume":"52","author":"Sevillano","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2012.07.009_bib0090","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/j.1875-9114.1997.tb03067.x","article-title":"Early switch from intravenous to oral antibiotics in hospitalized patients with infections: a 6-months prospective study","volume":"17","author":"Ahkee","year":"1997","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijid.2012.07.009_bib0095","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1177\/107327480000700211","article-title":"Intravenous to oral (IV:PO) anti-infective conversion therapy","volume":"7","author":"Wetzstein","year":"2000","journal-title":"Cancer Control"},{"key":"10.1016\/j.ijid.2012.07.009_bib0100","unstructured":"Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twentieth informational supplement. Document M100-S20. Wayne, PA: CLSI; 2010."},{"key":"10.1016\/j.ijid.2012.07.009_bib0105","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00013542-200310000-00003","article-title":"Acute pyelonephritis in adults: an update","volume":"14","author":"Horcajada","year":"2003","journal-title":"Rev Med Microbiol"},{"key":"10.1016\/j.ijid.2012.07.009_bib0110","first-page":"1172","article-title":"A prospective study of ceftriaxone treatment in acute pyelonephritis caused by extended-spectrum beta-lactamase-producing bacteria","volume":"91","author":"Suankratay","year":"2008","journal-title":"J Med Assoc Thai"},{"key":"10.1016\/j.ijid.2012.07.009_bib0115","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/jac\/dki344","article-title":"Risk factor for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infection in Turkey","volume":"56","author":"Arslan","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2012.07.009_bib0120","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s15010-007-7083-y","article-title":"Risk factors for community-acquired urinary tract infection due to quinolone-resistant E. coli","volume":"36","author":"Colodner","year":"2008","journal-title":"Infection"},{"key":"10.1016\/j.ijid.2012.07.009_bib0125","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.medmal.2009.02.006","article-title":"Recommendation for good practice guideline for diagnosis and treatment of adult patients with community acquired bacterial urinary tract infection","volume":"39","author":"Caron","year":"2009","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.ijid.2012.07.009_bib0130","first-page":"1418","article-title":"A double-blind comparative study of ME1207 and cefteram pivoxil for the treatment of complicated urinary tract infections","volume":"54","author":"Aarakawa","year":"1992","journal-title":"Nishinihon J Urol"},{"key":"10.1016\/j.ijid.2012.07.009_bib0135","first-page":"536","article-title":"Antimicrobial activity and clinical study on ME1207 in urinary tract infections","volume":"40","author":"Yamauchi","year":"1992","journal-title":"Chemotherapy"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971212012143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971212012143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,28]],"date-time":"2024-04-28T19:18:24Z","timestamp":1714331904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971212012143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S1201971212012143"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2012.07.009","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}